Not Signed In -
Sibutramine |
Meridia; Sibutrimine |
Sibutramine Systematic (IUPAC) name 1-(4-chlorophenyl)-N,N- dimethyl-a-(2-methylpropyl)- cyclobutanemethanamine Identifiers CAS number 106650-56-0 ATC code A08AA10 PubChem 2215 DrugBank APRD00456 Chemical data Formula C17H26ClN Mol. weight 279.85 Pharmacokinetic data Bioavailability Resorption 77%, considerable first-pass metabolism Metabolism liver Half life sibutramine approx. 1h metabolite 1 14h metabolite 2 16h Excretion sibutramine and active metabol ...
Wikipedia - [full article]
Sibutramine Clinical Trials
- Use of Sibutramine in Smoking Cessation
ClinicalTrials.gov Identifier: NCT00037752 - Active, not recruiting
Cardiovascular Diseases; Heart Diseases; Obesity
- A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.
ClinicalTrials.gov Identifier: NCT00234988 - Active, not recruiting
Obesity
- A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients.
ClinicalTrials.gov Identifier: NCT00234832 - Active, not recruiting
Obesity
- LOSS- Louisiana Obese Subjects Study
ClinicalTrials.gov Identifier: NCT00115063 - Active, not recruiting
Obesity
- Efficacy of MK0557 in Combination With Sibutramine or Orlistat
ClinicalTrials.gov Identifier: NCT00533481 - Completed
Obesity
- Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes
ClinicalTrials.gov Identifier: NCT00433641 - Completed
Obesity
- A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.
ClinicalTrials.gov Identifier: NCT00261911 - Completed
Obesity
- Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS
ClinicalTrials.gov Identifier: NCT00463112 - Completed
Obesity; Polycystic Ovary Syndrome
- Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity
ClinicalTrials.gov Identifier: NCT00330525 - Completed
Obesity; Overweight
- Adolescent Weight Management Study
ClinicalTrials.gov Identifier: NCT00212173 - Completed
Protocol #1:Behavioral Therapy + Placebo or Sibutramine; Protocol #2: Behavioral Therapy + Meal Replacement or Conventional Food
- A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder
ClinicalTrials.gov Identifier: NCT00402584 - Completed
Binge Eating Disorder; Obesity
- A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects
ClinicalTrials.gov Identifier: NCT00134199 - Completed
Obesity
- The Assessment of a weight-gain agent for the Treatment of Olanzapine-Associated Anti-obesity Agent in Patients with Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
ClinicalTrials.gov Identifier: NCT00044187 - Completed
Schizophrenia; Psychotic Disorders; Bipolar Disorder
Resources
- Meridia (Drug Digest)
- Meridia: The truth about the appetite suppressant for weight loss. (Chase Freedom)
email this page
print this page
bookmark this page
feedback on this page
